Anti-BR3 mAb can control B cells either by (1) crosslinking cell surface BR3 with the FcγR on NK cells, resulting in Antibody Dependent Cell-mediated Cytotoxicity; or (2) blocking binding of the survival factor BAFF to its BR3 receptor. Illustration by Paulette Dennis.